Cardio3 BioSciences
Edison | Mar 28, 2014 07:25AM ET
Steady progress
FY13 results show year end cash of €22.1m. This will fund the current CHART-1 Phase III for cardiac regeneration and last throughout 2015. CHART-1 recruitment is stated to be on target to provide data by late 2015. C-Cure autologous stem cells are a potentially powerful novel treatment for patients with weakened, scarred hearts. C-Cure showed positive cardiac efficacy endpoints in Phase II and median heart output increased by 25% relative to baseline. The FDA has approved the part US-based CHART-2 design. The value remains at €77 per share.
Phase III: CHART-1 (EU) and CHART-2 (US-EU)
CHART-1 is a European Phase III trial with a hierarchical outcome score focused on mortality and morbidity. Patients will be in, or recovering from, late-stage (NYHA Class III and IV) heart failure and only pumping half or less of the normal amount of blood. Cardio3’s C-Cathez catheter is used to increase the retention of cells in the heart to around 36%, a 3.6 fold gain. Top-line data are due in late 2015 with EMA regulatory filings possible from 2016. Management has stated that recruitment is on target but numbers have not been released. If C-Cathez is FDA-approved, CHART-2 could also use C-Cathez, possibly improving its probability of success. CHART-2 has a six-minute walk primary endpoint with a 40 metre improvement threshold. CHART-2 may be partnered in the US to gain trial funding with a possible 2017-18 filing. The FDA agreed the CHART-2 design in January 2014. The C-CURE Phase II showed that C-Cure was safe and showed a 25% median relative increase in cardiac output. This enabled patients to walk further in the six-minute walk test.
FY13 results: Strong cash, refocused preclinical
Cardio3 had December 2013 cash of €22.1m with €2.5m of Walloon cash funding due to 2015 and €1.5m of repayment rescheduling. Manufacturing and clinical costs were €6.9m in total. R&D was €2.6m (including capitalised costs). The portfolio now focuses on GQR-4, an antibody to prevent cardiac reperfusion injury on acute treatment. Admin costs were €3.0m. Cash outflow before financing was €11.2m.
Valuation: Huge market, huge need, huge potential
Cardio3 may have a customised therapy for about a million moderate to severe heart failure patients in North America and the EU. The main Cardio3 market is the EU with the US being partnered. Total end-user sales could be €1.9bn with no immediate regenerative therapy competitors. Based on clinical probabilities of EU 40% and US 25%, the base case indicative value remains at €77 per share. Scenario risk variants range from €42 to €225 per share.
Get The News You Want
To Read the Entire Report Please Click on the pdf File Below
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.